Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Taiwanese Subjects With Higher-Risk MDS
NCT01201811Phase 4Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Started Oct 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01201811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01201811.